• The iGaming market is expected to reach $127 billion by 2027
• Golden Matrix Group provides turnkey gaming platforms giving iGaming operators access to over 10,000 games, state of the art loyalty and customer retention systems
• GMGI recently acquired and 80% stake in RKings, helping boost revenue 221% in Q1 to $8.48 million as it ventures into the Mexican markets and ESports industry

In 2021, the U.S. commercial gaming industry generated revenue of $53 billion, smashing the previous record set in 2019 at $43.65 billion. With new markets coming online, more records are almost certainly in the cards as evidenced by a Q1 record of $14.1 billion in nationwide revenue to start 2022. Although online gambling, or “iGaming” as it is colloquially called, is still not as popular as its land-based counterpart, the time has come, in the words of Betenemy.com, “for online casinos to be in the spotlights.” It’s anticipated that the iGaming market will reach $127 billion by 2027, growth that companies like Golden Matrix Group (NASDAQ: GMGI) intend to capitalize upon. The U.S. isn’t the only player at the table by any stretch of the imagination. Europe has a massive gambling population accounting for 49 percent of the global market, with estimates for 2022 gambling revenue around $100 billion. Online casinos are thriving in Europe, comprising 23 percent of the overall market. Asia Pacific, with its billions of inhabitants, is the world’s single biggest market, accounting for 32% of the $76.79 billion value of the global iGaming market in 2020. From its headquarters in Las Vegas, Nevada, Golden Matrix is a gaming technology company that develops and owns online gaming IP and builds configurable and scalable white-label B2B (business-to-business) gaming platforms for its international customers, primarily in the Asia Pacific region. The gaming IP includes tools for marketing, acquisition, retention, and monetization of users.  The platform is available in both desktop and mobile applications. Golden Matrix’s GM-X system, and newly launched GMX-Ag platform are a gold standard for the iGaming market, delivering access to 10,000+ games from over 25 leading game providers. More than 635 unique casino operations use Golden Matrix’s platform to serve more than 7 million registered players. The company made its entrance into the lucrative European markets with the acquisition of an 80% controlling interest in RKings Competitions Ltd. last November, with the option to acquire the remaining 20%. Based in England, RKings operates online competitions for players in the United Kingdom and Ireland where winners can take home exotic cars, vacations, electronics, and more. The acquisition of RKings was partially responsible for Golden Matrix revenue jumping 221% year-over-year in the first quarter to $8.48 million. As the online gaming industry continues to evolve, Golden Matrix is expanding horizontally and vertically. The company has submitted an application for a gaming license in Mexico where, once issued, it will roll-out its RKings iGaming tournament platform. Elsewhere, Golden Matrix is making its initial foray into the booming ESports market. The company is in an optimal position with its strong brand in Asia Pacific, effectively the birthplace of electronic sports and still the most robust marketplace in the world. Gambling on ESports has many unique sets of challenges to keep things fair and honest. To date, most major sports books only offer limited betting action on ESports and that is typically restricted to only games like the ever popular first-person CS: GO, and only during high-stakes tournaments where players are less tempted to potentially throw a game. Right now, Golden Matrix CEO Brian Goodman says his company is focusing on peer-to-peer Esports betting, another area that has been highly touted for its potential because bets can be customized and eliminate “the house” and setting the odds. Plus, peer-to-peer bets on Esports aren’t subject to as many regulatory restrictions as bona fide gambling operations, such as sports books and online casinos. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

• QSAM Biosciences Inc. is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients
• CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical being evaluated for multiple indications
• CycloSam has been shown to cause significantly less buildup of long-lived radionuclidic impurities than prior FDA-approved drugs
• There is significant precedent that the radioisotope used in CycloSam, Samarium-153, is effective in treating bone cancer, as demonstrated in a published study conducted in over 500 patients using an older formulation of the drug
• There is also significant preliminary safety precedent for Samarium-153, as shown through the 2020 single patient IND and the super-therapeutic dose administered in that study
• QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio
• The company is led be an experienced management team with an extensive record of FDA approvals, big pharma partnerships and M&A transactions

QSAM Biosciences (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients. QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas. CycloSam(R) CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial. CycloSam(R) has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs. The indications for CycloSam(R) currently being evaluated by QSAM Biosciences include:

• Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam(R).
• Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam(R) to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
• Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (“IND”) study, an investigator concluded that high-dose CycloSam(R) can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union. Market Outlook Through its ongoing development of CycloSam(R), QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children. Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

• Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
• Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
• The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam(R) for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs. Management Team QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions. Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam(R), and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University. Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas. Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina. For more information, visit the company’s website at www.QSAMbio.com. NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM

• EverGen Infrastructure CEO, Chase Edgelow, was recently featured on IBN’s Bell2Bell podcast
• Edgelow elucidated on the origins of the company as well as its commercial objectives going forward
• EverGen recently purchased a 50% stake in an Ontario-based RNG project, with a cumulative production capacity of 1.7 million GJ per year

Chase Edgelow, Co-Founder and CEO of EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF), a British-Columbia based Natural Gas operator, was recently featured on the latest episode of the InvestorBrandNetwork’s Bell2Bell Podcast, with Edgelow seizing on the opportunity to expand on EverGen’s business model and operating markets (https://ibn.fm/s1tdx). Edgelow separately elaborated on EverGen’s recent announcement of its entry into definitive agreements with Northeast Renewables LP to acquire a 50 percent interest in a portfolio of Ontario-based renewable natural gas (“RNG”) development projects. Drawing from his background working at one of the world’s largest infrastructure asset managers, Edgelow initially expounded on the commercial philosophy underpinning his decision to co-found EverGen in 2020. “[In my previous role] I had an emphasis on finding assets that we could acquire or companies we could partner with where there was long-term contracted cash flow. In this environment, that stability of earnings is something that is highly sought-after,” Edgelow added. “[My co-founder and I] really wanted to find an opportunity to replicate some of that success in our own business, so we came up with EverGen”. Whilst setting out to create a stable, cash-generative business, Edgelow and co-founder, Mischa Zajtmann were simultaneously able to mold EverGen into a significant player within Canada’s renewable energy sector – helping drive the nation’s power grid’s transition towards a more sustainable, and carbon-free future. “We are a renewable natural gas energy company. We’re a developer, owner and operator of projects that take organic waste and convert that organic waste into renewable energy in the form of renewable natural gas (‘RNG’),” Edgelow said. “[Canadian utilities, like FortisBC] offer 20-year contracted offtakes to companies like ours to supply them with green energy, which provides a certainty for our business. Our business is then going out and building facilities that will take organic waste and convert it into RNG.” EverGen has sought to cater to the growing demand for renewable natural gas over the past two years, aggressively developing and expanding upon its supply capabilities. In addition to the company’s ownership of Fraser Valley Biogas, Western Canada’s first RNG facility which has been in continuous operation since 2011, EverGen also manages two composting and organic processing facilities, which will be expanded to combine anaerobic digesting and biogas upgrading technologies to produce RNG from the manure generated by local dairy farms as well as other organic waste. More recently, EverGen Infrastructure revealed that the company had purchased a 50% stake in a portfolio of renewable natural gas development projects in Ontario, Canada from Northeast Renewables (https://ibn.fm/afivq). The deal, which saw EverGen pay a gross cash consideration of $1.5 million, has a targeted cumulative production capacity of approximately 1.7 million gigajoules (“GJ”) per year, with projects set to come online between 2023 and 2024. Ultimately, EverGen expects the Ontario-based project to more than triple its RNG capacity to upwards of 1 million GJ per year. “The acquisition of Project Radius provides a foothold in Ontario – a new and strategic jurisdiction in which EverGen can continue to participate in the consolidation and growth of the RNG industry in the near-term, as well as benefit from project economics in line with or exceeding those we have seen with our initial projects,” Edgelow stated in relation to the stake purchase. “Ontario has an abundant amount of excess organic feedstock, and as a leader in the RNG industry, EverGen can develop the sustainable infrastructure that contributes to carbon-negative energy production and the greening of the province.” For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Daniel Brody, Eat Well’s Co-Founder and Director, has, since June 29, 2022, been buying shares in the company, totaling 8,430,625 as of June 29, 2022
• His purchases highlight his confidence in the company’s current trajectory and its commitment to creating shareholder value
• Eat Well maintains that its revenue guidance for its investee companies still stands at $90 million to $110 million for the 2022 fiscal year

The past year was monumental for Eat Well Investment Group (CSE: EWG) (OTC: EWGFF). Most notably, it marked the company’s market expansion following partnerships with vital retail companies in the United States and Canada, with customers in over 35 countries worldwide. In addition, the period saw the company grow its product offering in a move that aimed to grow its market share and create value for its shareholders. Going forward, Eat Well’s management has shared its plan to increase its production, specifically of its portfolio company Belle Pulses. Known for producing approximately 90,000 metric tons of protein in 2021, this company now seeks to increase its capacity to nearly 100,000 metric tons annually in Canada, with an additional 15,000 in the U.S (https://ibn.fm/rXUEA). “Shareholders should know that Belle is increasing its production capacity as it is our goal to help support the global food industry,” noted Mark Coles, Eat Well’s Chief Investment Officer (“CIO”). “We will continue to expand Belle’s operations and are looking forward to showing the world its ability to procure, process, and deliver proteins to the international marketplace,” he added. Such moves by Eat Well have elicited confidence from investors and shareholders, the most notable being the company’s Co-Founder and Director, Daniel Brody. Since June 20, 2022, Mr. Brody has been buying more shares in the company, with the most recent completed purchase dating June 29, 2022, equating to over 2,175,000 shares bought this month. Consequently, his shares currently stand at 8,430,625, and it is further projected that he will continue investing in the company (https://ibn.fm/cR2Tn). The plant-based foods market is projected to account for 7.7% of the global protein market by 2030 at over $162 billion. Bloomberg further notes that plant-based alternatives are here to stay and that consumption will only go up as time progresses. Eat Well understands this opportunity, hence its strategic positioning in the industry. Together, these factors point to the company’s strength and investment potential, as has been evidenced by Daniel Brody’s stock purchases. For 2022, Eat Well plans to scale up operations further for its portfolio companies. Belle Pulses’ management has projected an improved margin performance, with Amara continuing to bank on its 6,000 distribution points across North American retail to achieve its revenue targets (https://ibn.fm/3ngwj). To that effect, Eat Well maintains that its revenue guidance for its investee companies still stands at $90 million to $110 million for the 2022 fiscal year. Additionally, the company has cited that its bottom-line profitability of combined investments is projected to improve throughout the calendar year, showing how much value the company is creating for its shareholders and why it is worth investing in. For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

DGE’s 2nd Chief Patient Officer Summit being held on July 19-20, 2022 in Boston, MA is attended by industry leaders who offer valuable advice on the best practices for building trusted long-term relationships with patients, caregivers, and advocates. They offer their insights on cultivating a corporate culture dedicated to providing the best possible patient experience. Previous coverage of this topic has been applauded, where dignitaries dedicated to patient advocacy, engagement, education, and communication, all discussed how a patient’s opinion is critical and integrated into discovery research, clinical studies, and post-approval. The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing B2B events. The global event company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.  The in-person DGE summit will include keynotes, and panel discussions, and offers learning experiences from leaders for integrating patient preferences in order to create a more meaningful alliance. Important topics of discussion points include:

• Discuss and organize patient advisory boards, consultant programs, and patient counsels, to engage patients and note their preferences
• Embrace the global landscape of patient advocacy, and tune in to the culture, language, and local regulatory codes and guidelines
• Understand the legal aspects and compliance risks for relationships with patients, caregivers, and advocacy organizations
• Interact with patients to get their valuable feedback to improve alliances

Patient advocacy professionals will discuss how to put the patient first, from pre-clinical to post-approval. Panel discussions include reviewing opportunities for patient engagement, and global strategies for harmonious communication among health equity-focused patient organizations. The main emphasis of the event is to improve communication across the medical spectrum for an enhanced patient experience. To know more about the event, please visit https://ibn.fm/922Tg.

• Correlate Infrastructure Partners is known for executing portfolio-scale renewable energy and efficiency upgrades across the U.S.
• With a recent study observing that more CEOs are now prioritizing sustainability, the market is clearly growing for Correlate’s services
• Correlate helps companies deal with some of the key challenges identified in the study, including concerns about the return on investment and economic benefits, lack of insights from data, inadequate skills, and general technological barriers
• Correlate funds, designs, engineers, and builds sustainability-focused projects in addition to providing the technical expertise through its team of energy experts, and in a way that makes sustainability compellingly affordable

Sustainability is increasingly gaining prominence as part of the mainstream corporate agenda. A recent study by the Institute for Business Value (“IBV”), a think tank that is part of IBM Corporation (NYSE: IBM), notes that “CEOs who successfully integrate sustainability and digital transformation report a higher average operating margin than their peers.” The IBV study, which drew insights from interviews with 3,000 CEOs from over 40 countries, showed that 37% more CEOs in 2022 than in 2021 consider sustainability a top priority. More significantly, 83% anticipate sustainability investments will yield improved business results in the next half a decade (https://ibn.fm/m348T). The CEOs, however, mentioned a number of hurdles that could hinder the achievement of their sustainability objectives. Chief among the challenges cited by most CEOs, 57%, is the unclear return on investment (“ROI”) and economic benefits of sustainability investments. Others include regulatory and technological barriers, lack of clear insights from data, and inadequate skills for moving forward. The study, nonetheless, singled out strategy, committed leadership, and strategic partnerships, as some of the key drivers and differentiators that could enable companies to deal with these hurdles and attain sustainability. “Solving the world’s most vexing social and environmental problems demands strategic collaboration and innovative approaches within and across industries,” an excerpt from the report reads (https://ibn.fm/l6cOX). In Correlate Infrastructure Partners (OTCQB: CIPI), a company with an extensive track record in executing portfolio-scale renewable energy and comprehensive efficiency upgrades across the United States, CEOs looking to solve social and environmental problems find that strategic partner and innovator. With Correlate, the company’s website notes, sustainability and profitability are no longer at odds. CIPI makes it far easier for organizations to attain their Environmental, Social, and Governance (“ESG”) and Net Operating Income (“NOI”) goals. This is accomplished through a low-cost model that minimizes risk and guarantees value, greatly reducing the wasting of time and money. With executives citing ROI and economic benefits as some of the major hurdles to sustainability investment, it’s a major selling point that Correlate’s funding mechanisms for renewable energy projects and efficiency upgrades deal directly with these concerns. “Our funding mechanisms don’t require out-of-pocket capital expenditures (“CapEx”). Because our solutions are cash flow positive, you can rapidly capture the full value of opportunities and increase net operating income,” CIPI’s website reads. Important as it is, funding is just one of the benefits client companies realize by partnering with Correlate. Others include unsurpassed technical expertise when it comes to efficient technological solutions and analytics. CIPI relies on a team of energy experts to develop a customized operating strategy that fits each organization’s portfolio. This team utilizes analytics that combines the clients’ facility and utility data and their corporate energy goals, creating a clear and useful foundation that helps them identify the most impactful measures affecting NOI when solutions are installed or deployed. CIPI designs, engineers, and builds the projects, collaborating with its clients’ existing partners to ensure that all parties are working efficiently toward the same goal. Correlate deploys its software platform, which monitors, measures, and optimizes numerous building performance metrics before, during, and after the completion of the installations and upgrades to identify energy improvement opportunities. The market for Correlate’s services appears set for healthy expansion, consistent with industry reports. Analysts at Reports and Insights, for instance, project that the energy-efficient building market will grow from a value of $235.7 billion in 2020 to $476.4 billion by 2028, representing a 9.2% CAGR (https://ibn.fm/4EnEr). At the same time, a market outlook report by Allied Market Research estimates the global renewable energy market will expand at a CAGR of 8.4% from 2021 to 2030. This growth will see the value increase from $881.7 billion in 2020 to an estimated $1.978 trillion by 2030 (https://ibn.fm/8dyVR). For more information, visit the company’s website at www.CorrelateInfra.com.

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• The company’s platform Generates New Rent and Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

For more information, visit the company’s website at www.CorrelateInfra.com. NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Biopharma industry analysts have been expecting 2022 to be a heady year for big-pharma acquisitions or partnerships with promising medical upstarts following a time period that has left the biggest companies flush with cash
• Among promising device and drug developers, Odyssey Health Inc. has been working on novel solutions to brain concussion injuries, a rare neurodegenerative disease, obstructive choking incidents and early-stage coronary artery disease (“CAD”) detection
• Odyssey Health Inc. is taking its brain concussion solution to a Phase 1 clinical human trial currently with possible progression to Phase 2 before the end of the year
• The company likewise anticipates it could advance its two device products for FDA submission by year’s end and on to potential commercial development

As 2022 got under way, the biopharma world was trying to predict where the major acquisitions for the year would take place and how much would be spent on M&A, given the cash-flush environment of big-pharma, particularly for those successful in responding to COVID-19, and the patent cliffs many of those companies are facing (https://ibn.fm/IUXaV). Halfway through the year, deal values are down by 58 percent and volume has decreased by 33 percent, according to professional services firm PwC. And yet the company’s analysts are continuing to predict a flurry of activity will bring equilibrium to industry outlooks by year’s end as big-pharma hunts for biotechs focus on early-stage companies and bolt-on transactions (https://ibn.fm/Hc5rS). That class of deals is exemplified by recent M&A efforts by Pfizer to acquire migraine therapy innovator Biohaven (https://ibn.fm/NBS7x) and partner with “mystery startup” Priovant, an autoimmune disease biotech unit of Roivant (https://ibn.fm/FasFg), while Bristol Myers Squibb is dealing with the adoption of cancer drug maker Celgene (https://ibn.fm/BPHlG). Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY) is optimistic about the trend as the company continues to dedicate its operational strategy toward the acquisition and creation of lifesaving medical products. Odyssey’s portfolio includes medical device candidates and pharmaceutical products in development that are responsive to conditions such as heart disease, foreign object-induced choking, neurodegenerative disorders and brain concussion injuries. One drug product designed to treat mild traumatic brain injury within the first few minutes after an incident is advancing in a Phase 1 clinical human trial following on preclinical lab animal tests that provided encouraging data, CEO Michael Redmond said in a June interview (https://ibn.fm/QCCH4). No U.S. Food and Drug Administration (“FDA”)-approved drug exists at this point, creating a particular opportunity for the company. The other drug substance is a novel compound intended to treat neurodegenerative Niemann-Pick disease, which leaves patients with an average lifespan of five to 20 years beyond diagnosis. The company’s device technology includes a monitoring and screening device for early detection of coronary artery disease and a handheld choking rescue device (https://ibn.fm/MUhfe). “We could be in commercial — with proper funding and if we meet our technical goals — we could be into the FDA by the end of this year with both of those products,” Redmond said. For more information, visit the company’s website at https://odysseygi.com/. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Lexaria is a global innovator in drug delivery platforms; its patented DehydraTECH(TM) technology improves the bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“API”)
• Testing confirms that DehydraTECH-processed cannabidiol beverages maintained 93.4% and 78% potency of CBD a full year and two years after production, respectively
• Lexaria recently signed two agreements with BevNology LLC, an Atlanta-based company with advanced capabilities that support best-in-class beverage formulations
• The partnership, which also leverages Lexaria’s superior DehydraTECH-CBD nanoemulsification formulation and processing techniques, could make industry-leading beverage products a reality for many brands

In this year’s letter to shareholders, Lexaria Bioscience (NASDAQ: LEXX) Chair and CEO Chris Bunka acclaimed the company’s research and development achievements which had resulted in remarkable stability of DehydraTECH(TM)-processed cannabidiol (“CBD”) beverages. One year after production, Bunka wrote, “bottled consumer beverage contained a remarkable 93.4% potency of CBD. We also showed less than 1% variability of CBD potency within the beverage, a concept of critical importance when delivering drugs in an aqueous solution” (https://ibn.fm/uhiIf). The latest data from stability testing undertaken 25 months after initial bottling show the product had higher variability but still retained an average 78% of originally formulated CBD. Additionally, the microbiologic purity and cleanliness of the product surpassed all requirements 25 months after bottling. One problem that has long caused the instability and variability of cannabis drinks, which normally include cannabinoids such as CBD and tetrahydrocannabinol (“THC”), is the hydrophobic nature of the cannabinoids. When THC or CBD are extracted from the cannabis or plant, they take an oil-based form. And as a Prepared Foods article notes, this hydrophobic nature complicates their use, particularly in water-based products. Studies have, in fact, shown that the insolubility of CBD, for instance, results in bioavailability as low as 4%. But companies can get around this problem using adequate manufacturing techniques that employ encapsulation and emulsification (https://ibn.fm/sanbV). “First and foremost, encapsulation allows for even dispersion throughout the product, meaning consumers will get the same amount of an active ingredient, such as CBD or THC, in each bite or sip,” reads the Prepared Foods article. “Encapsulation also improves a product’s shelf life, preventing the cannabinoid content from degrading over time and keeping the formulation stable.” On the other hand, emulsification, which involves using a binding agent known as an emulsifier, aims to improve the absorption and onset times. There are three types of oil-in-water emulsions, macro, micro, and nano, with nanoemulsions featuring prominently in the cannabis food and beverage industry. Lexaria understands the impact of adequate manufacturing techniques on the potency of its DehydraTECH-processed CBD products. And in a recent move that expands its manufacturing prowess even further, the company recently signed two agreements with BevNology LLC, a leading Atlanta-based beverage development and advisory company focused on providing quality formulation and commercialization services of cutting-edge beverage products (https://ibn.fm/pJVrz). One of these agreements, a manufacturing operating agreement, expands production capabilities for Lexaria’s own growing list of business-to-business (“B2B”) clients looking to purchase DehydraTECH-powered active ingredients for consumer-packaged-goods brands. BevNology custom-built a new, state-of-the-art processing facility that expands production capacity substantially. Already, the facility is operational and serving Lexaria’s clients. On its part, Lexaria installed all required commercial DehydraTECH manufacturing equipment into the facility in anticipation of future growth. Meanwhile, the second agreement, a commercial license agreement, authorizes BevNology to offer DehydraTECH products with hemp-derived active ingredients, including CBD, under BevNology and partnered brands. This agreement leverages BevNology’s advanced capabilities that support best-in-class beverage formulations coupled with Lexaria’s superior DehydraTECH-CBD nanoemulsification formulation and processing techniques, could make industry-leading beverage products a reality for many brands. “These agreements build on a long-standing and very successful product development consulting relationship between Lexaria and the expert scientists and personnel at BevNology,” commented Chris Bunka. “BevNology’s formulation and production capabilities are class leading, and we are confident that our new relationship with our trusted partner will propel new and exciting growth opportunities for both companies.” Lexaria Bioscience is a global innovator in drug delivery platforms, its patented DehydraTECH technology improves the bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“API”). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• U.S.-based mobile communications technology services provider FingerMotion is a China-focused innovator building revenues in the cell phone and reinsurance markets
• China recently reinforced its interest in seeing mobile payments and financial technology platforms playing a larger part in its developing economic strategy for strengthening its internal domestic consumerism
• FingerMotion recently reported annual financial data that showed revenue had grown by 37 percent during last year with 297 percent growth in its big data revenue and 170 percent growth in telecommunications products and services
• China has an estimated 1.4 billion mobile users, and market analysts predict mobile engagement there will grow at a CAGR of 44.7 percent between 2020 and 2027

Evolving mobile technology services provider FingerMotion (NASDAQ: FNGR) is building a deeper channel for revenue in its services for China’s mobile phone users and big data clients as the nation’s government signals new interest in finding solutions to some of its regulatory concerns for the market in general. China President Xi Jinping recently encouraged mobile payments and financial technology platforms to “play a bigger role” in strengthening the country’s economy, which is the second-largest in the world (https://ibn.fm/mlTwA). The technology platforms are viewed as key players in supporting the country’s dual circulation economic goal — a new buzzword that describes the nation’s growing emphasis on strengthening its domestic consumer market while continuing to sustain its international exports (https://ibn.fm/I3hhy). FingerMotion’s central competencies are in mobile payment and mobile recharge platform solutions, but the company has been expanding into big data services through its Sapientus division. The data services have primarily been marketed as a tool for reinsurance companies as they they look for effective measures of risk scoring and ways to simplify policy underwriting purchasing, but FingerMotion has acknowledged it could expand into other industries at some in the future. “We’ve always thought of the ability of the algorithms that we have. It’s not really just to perfect those algorithms but it’s also to have them exportable and replicated in other jurisdictions, in other markets,” CEO Martin Shen said during a corporate conference call last year (https://ibn.fm/LbDcC). “But again, that takes time to develop. … Right now, let’s just build and make sure that our foundation is strong first.” The year-end financial summary presented by FingerMotion in early June showed annual revenue had grown by 37 percent during last year to $22.93 million, with 170 percent growth in the company’s telecommunications products and services as well as 297 percent growth in its big data revenue (https://ibn.fm/U0LtZ). Mobile top-up and short and multimedia messaging (SMS and MMS) services have remained the primary drivers of the company’s revenues, serving the interests of China’s estimated 1.4 billion mobile users, most of whom were born after Internet and mobile technology began to develop at a breakneck pace in the 1990s and are now actively the country’s manner of interpersonal communication through social media as “digital natives” (https://ibn.fm/zqkCJ). China’s leading world position as a developer of 5G wireless technology and its use have further made it fertile ground for expanding marketing and purchasing services (https://ibn.fm/a8ocr). Market analysts at Reportlinker.com forecast mobile engagement in China growing at a CAGR of 44.7 percent between 2020 and 2027, commanding $22.4 billion of the global $90.7 billion in revenues predicted by that point (https://ibn.fm/p6PgH). For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Fuelpositive Corp. offers its flagship product, a containerized green ammonia production system which provides environmental-friendly energy solutions across multiple industries
• Company’s green ammonia technology is modular and scalable, and produces green ammonia onsite, thereby eliminating problems posed by highly polluting traditional ammonia production and an unreliable supply chain
• Fuelpositive’s carbon-free NH3 can also play a vital role in enabling the hydrogen economy

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) s a growth-stage technology company engaged in providing energy-efficient solutions that are commercially viable and sustainable. Their flagship product, a containerized green ammonia production system, can be used across a spectrum of industries, with special significance for agricultural fertilizers, and offers innovative solutions that address environmental concerns and unpredictable supply chain risks. FuelPositive’s containerized green ammonia production system was developed by Dr. Ibrahim Dincer and his team at the University of Ontario Institute of Technology (“UOIT”)  (patent-pending). The ammonia is manufactured onsite from water and air, using a sustainable electricity source – thereby producing green ammonia that is entirely carbon-free. The system is modular, scalable, and fits in standard shipping containers that are placed where the green ammonia is needed. This decentralized approach avoids the hurdles posed by the unreliable supply chain and wildly fluctuating prices that end users have been struggling with over recent years. Users produce green ammonia when and where they want, in the right quantities. This mechanism is ideal for the fertilizer industry, where more than 80% of the world’s ammonia is used. FuelPositive Corp. has filed a U.S. Non-Provisional Patent Application for the company’s “Modular Transportable Clean Hydrogen-Ammonia Maker” with the United States Patent and Trademark Office. FuelPositive has also filed a companion Patent Co-Operation Treaty (“PCT”) Patent Application preserving FuelPositive’s right to its proprietary invention in all 156 PCT member states (https://ibn.fm/g1UQ9). FuelPositive’s demonstration units are being built to produce up to 300 kg/day, which is enough to provide fertilizer and fuel to thousands of acres of agricultural lands. The company’s first demonstration production system will be set up in Manitoba, Canada in fall 2022. Similar demonstration pilot projects will follow. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF